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Neglected Diseases
T
hrough its impact on worker productivity, premature 
disability, and death, Chagas disease accounts for 
670,000 disability-adjusted life years per annum [1]. 
This makes it the most important parasitic disease of the 
Americas. It is both a disease of poverty (Figures 1 and 2) 
and, like other neglected tropical diseases, also “poverty 
promoting” [2]. Traditionally conﬁned to Latin America, 
Chagas disease is becoming an important health issue in 
the United States and Europe. First, due to the continuous 
inﬂux of immigrants from disease-endemic countries in Latin 
America, a proportion of whom are infected with Trypanosoma
cruzi, an increasing number of infected subjects are seen 
in clinical practice, whether, for example, through routine 
screening of US blood and organ banks [3] or physicians’ 
ofﬁces in Europe [4]. The appearance of T. cruzi in US 
blood banks led to the implementation of the ﬁrst Food and 
Drug Administration–approved diagnostic blood screening 
test for Chagas disease earlier this year [5]. Second, an 
increasing number of autochthonous Chagas disease cases 
have been reported in the US [6,7], which may mirror the 
increased reporting of T. cruzi infection in domestic animals 
and wildlife. Recognizing that Chagas disease can no longer 
be considered an “exotic” disease in the US, the American 
Society of Tropical Medicine and Hygiene held a clinical 
course in Chagas disease prior to its 2007 annual meeting 
(http://www.astmh.org/meetings/premeeting.cfm#clinical).
Despite estimates of up to 15 million existing cases and 
50,000–200,000 new infections per year, funding for research, 
prevention, and control has been limited, and therapeutic 
options remain unsatisfactory. Consequently, several 
editorials and perspectives have recently drawn attention 
to Chagas disease and T. cruzi [8–10]. While these papers 
highlighted the impact of this disease on public health in the 
Americas, and rightly pointed out that major achievements 
have been made in its control, they failed to emphasize 
several key challenges that are currently undermining these 
achievements and that must be urgently addressed in order 
to move to the next stage: ensuring the long-term and 
sustainable control of this devastating disease.
Etiology, Distribution, and Clinical Manifestations
Chagas disease (also known as American trypanosomiasis) 
is named for the Brazilian physician Carlos Chagas, who 
discovered the disease exactly a century ago and published 
its ﬁrst description in 1909. It is caused by the protozoan 
parasite T. cruzi and is found in wildlife, domestic animals, 
and humans throughout much of rural as well as peri-urban 
areas of Mexico, Central America, and South America. In 
the US T. cruzi has been reported in dogs and a range of 
wild animals (e.g., raccoons and opossums), with human 
cases being relatively rare [6,7]. T. cruzi is mainly transmitted 
through blood-feeding triatomine bugs, but can also occur 
congenitally [7,11], through blood transfusion [12] or 
organ transplantation [13], and through the ingestion of 
contaminated food or ﬂuids [14]. The complex life cycle 
involves different parasite life stages in both vector and host, 
all highly adapted to their respective environments, which 
maximizes transmission potential and/or host immune 
evasion and, hence, long-term parasite survival (http://www.
dpd.cdc.gov/dpdx/HTML/TrypanosomiasisAmerican.
htm#Life%20Cycle).
Most infected people do not know that they have become 
infected, as—in the disease’s acute stage—the symptoms are 
benign (e.g., fever, swollen lymph glands, and, occasionally, 
an inﬂammatory reaction at the biting site or a swollen eye) 
or very rare (severe myocarditis or meningoencephalitis) 
[15]. Symptoms of acute infection may last up to a few weeks 
or months, and parasites may be found in the blood during 
this stage. Infections then remain largely asymptomatic 
(with few or no parasites found in the circulation), often for 
years or even decades, until up to 30% of patients develop 
chronic Chagas disease, i.e., cardiac or gastrointestinal 
complications, which if left untreated are severely debilitating 
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and in many cases, fatal [15]. Chagas cardiomyopathy, 
which may result in cardiac arrhythmias, apical aneurysm, 
congestive heart failure, thromboembolism, and sudden 
cardiac death (Figures 3 and 4), is the most common form 
of cardiomyopathy in South and Central America and the 
leading cause of cardiovascular death in disease-endemic 
areas [16]. In people with suppressed immune systems (e.g., 
due to HIV/AIDS or chemotherapy), Chagas disease can 
reactivate with abundant parasites found in the blood and 
tissues. Because of its potentially long asymptomatic phase, 
however, Chagas disease is often considered a “silent killer” 
[9], which is one of several reasons why it fails to attract 
media attention. 
Grim Outlook 1: The Challenge of Vector Control 
Tools to manage Chagas disease are numerous but are 
severely limited with regard to crucial aspects of prevention, 
detection, and treatment. Current vector control methods 
and strategies have signiﬁcant limitations, diagnostics are 
variable and of unknown reliability, drugs for treatment are 
inadequate, and vaccines are nonexistent. Yet some bright 
spots exist, such as the decrease in transmission that has been 
achieved through control of insect vectors and screening of 
blood and blood products. 
The “Southern Cone” initiative [17] has knocked down 
transmission rates dramatically in the southern tier of South 
America and is credited with interrupting vector-borne 
transmission via Triatoma infestans in Uruguay, Chile, and 
Brazil, primarily through insecticidal spraying of houses. 
However, elimination of T. infestans (one of the program’s 
stated objectives) has not been achieved in the core of its 
distribution throughout the hyperendemic Gran Chaco region 
spanning northern Argentina, Paraguay, and Bolivia. Success 
may even be more difﬁcult elsewhere in Latin America where 
there are many different vector species, each with distinct 
feeding and infestation behaviors, while in some endemic 
countries, notably Mexico, no control programs for this 
disease have ever been established. Among the many problems 
with exclusive reliance on insecticides is that prevention of 
re-infestation of houses by the insect vectors requires repeated 
spraying, which also promotes the development of insecticidal 
resistance—an outcome that is already documented in 
Argentina [18] and is increasingly detected in Bolivia. There 
are alternative insecticides, but their use is accompanied by 
added problems of higher costs or increased toxicity. 
The decentralization of health services in many endemic 
countries combined with declining funding for control 
efforts has transferred the burden of control to provinces 
or local communities that are ill-equipped to supply these 
services. Even if vector control were better coordinated and 
fully funded, eradication of either the many domestic vector 
species or the parasites is not feasible for this zoonosis. 
Potentially, improvements in housing could permanently 
reduce vectorial transmission. However, at a minimum 
cost of US$200 to more than US$2,000 per house [19], 
such improvements will have to await signiﬁcant economic 
development in endemic areas or speciﬁc investments for 
housing improvements on the order of US$10 billion. 
Grim Outlook 2: The Challenge of Chemotherapies and 
Vaccines
The current chemotherapies for T. cruzi infection and 
Chagas disease have many shortcomings, as do those in drug 
discovery and development. The available compounds for 
treatment, benznidazole (Rochagan, Roche Pharmaceuticals) 
and nifurtimox (Lampit, Bayer HealthCare), both have 
severe side effects, require long courses of treatment, and 
exhibit variable efﬁcacy [20]. At present, the World Health 
Organization and other sources indicate that these drugs are 
active only in the acute and short-term (up to a few years) 
chronic phase (http://www.who.int/tdr/diseases/chagas/
direction.htm). A number of studies now provide reason to 
doi:10.1371/journal.pmed.0040332.g001
Figure 1. Chagas Disease Is Closely Linked to Poverty and Socioeconomic Development, and Poor Housing In Particular
Example of a typical household environment in Chagas disease–endemic areas: mud-and-thatch house with a front veranda (in the background) and 
storage area (in the front), located in the dry Chaco forest around Amamá village, northern Argentina.PLoS Medicine  |  www.plosmedicine.org 1854 December 2007  |  Volume 4  |  Issue 12  |  e332
question this recommendation [21–27]. Although some of 
these studies were non-controlled and used cure parameters 
that may be debatable because of the absence of a diagnostic 
gold standard (see below), they have been remarkably 
consistent in showing moderate to signiﬁcant efﬁcacy in long-
term chronic infections. Thus, whilst waiting for the results 
of, for example, the BENEFIT trial (http://clinicaltrials.
gov/ct/show/NCT00123916?order=1) evaluating the efﬁcacy 
of benznidazole in chronic Chagas disease patients (expected 
to be completed in 2011), and unless or until better drugs are 
available, benznidazole and nifurtimox should be more widely 
used, based on the published evidence that such compounds 
may reduce the parasite burden and moderate disease 
progression in all stages of the disease [21–28]. It would 
therefore be ethically questionable to restrict the drugs’ 
use to only patients with a deﬁned duration of (acute and 
short-term chronic) infection, as currently recommended. 
However, the decision to treat chronic patients with these 
drugs should be made on a case-by-case basis, only after 
thorough clinical assessment and with continuous monitoring 
of potential side effects.
Academic and other noncommercial drug discovery efforts 
have yielded an increasing number of targets and new drug 
candidates, but surprisingly few of these promising leads have 
moved beyond the discovery/candidate stage. This stalemate 
is due in part to limited funding for further research and 
development, but even with drugs that have been available 
for more than 25 years, such as benznidazole, deﬁnitive 
preclinical evidence of cure in animal models is strikingly 
absent. A recent report from the Wellcome Trust–supported 
Pharmaceutical Research and Development Policy Project 
concluded that there is increasing industrial interest and 
progress in drug development for neglected diseases 
[29]—but this is certainly not the case for Chagas disease. 
Indeed, promising compounds such as Schering-Plough’s 
posaconazole have yet to be further pursued as anti–T. cruzi 
drugs, despite extensive and promising preclinical data [20]. 
The success of drug treatment in arresting disease 
progression in subjects who have been infected for more than 
20 years [21,22], coupled with a wealth of other data, has 
recently prompted a welcome shift toward studying Chagas 
disease as a problem of parasite persistence, rather than 
primarily as a problem of an inappropriate or imbalanced 
immune response [30]. This shift has also generated more 
interest in vaccines as a vehicle for control or treatment. Even 
so, vaccine development for T. cruzi infection has had a very 
slow start and remains nonexistent as a strategy for control 
or prevention. There are substantial potential problems with 
vaccines for Chagas disease, not the least of which include 
how one would test a conventional prophylactic vaccine for an 
infectious illness that is rarely detected until years or decades 
after the initial infection. However, given the cost-effective 
nature of vaccines and potential innovative applications (e.g., 
in transmission blocking or as therapeutics), more research 
is warranted, and vaccines should be included in the overall 
long-term strategy for control, prevention, and treatment of 
T. cruzi infection.
Key Needs and Opportunities: Diagnostics and 
Integrated Vector Control
One of the key issues concerning Chagas disease is that of 
diagnosis. Without effective diagnostics, infected individuals 
cannot be identiﬁed and thus treated, and the effectiveness 
of treatment cannot be efﬁciently assessed. Moreover, the 
effectiveness of any control campaign, whether targeted 
at insect vectors, blocking of transmission, or vaccination 
of individuals, cannot be measured without competent 
diagnostics. Transmission via blood transfusion or tissue 
transplantation has been a point of concern for many years 
in Latin America but has only come to the fore in the US and 
Europe as the number of immigrants unknowingly carrying 
T. cruzi has increased. Most current serological tests, whether 
developed in-house or purchased commercially, employ 
crude antigen preparations from inappropriate parasite life-
cycle stages (i.e., epimastigotes—which are present in the 
insect vector but not in mammalian hosts). Development 
of tests using one or more recombinant proteins/peptides 
may be an improvement, but even these tests often provide 
inconsistent and/or unreliable results [31–33]. The absence 
of a true gold standard (i.e., a method to consistently detect 
the presence of parasites in those individuals with T. cruzi
infection) makes evaluation of the sensitivity of serological 
tests difﬁcult. It is standard practice to use test sera that 
are positive on multiple other serological tests to assess the 
sensitivity of new tests, proving that any new test is no worse, 
but not necessarily any better, than existing ones. However, 
it is well documented that individuals with conﬁrmed 
infection are typed as inconclusive or negative on multiple 
existing serological tests [34–36]. The design of tests to 
detect these inconclusive or “conventional seronegative” 
subjects has not been a priority. Likewise, the development of 
technologies that can more rapidly assess treatment efﬁcacy, 
diagnose congenital infections, or determine the impact of 
transmission control methods has been slow. Fortunately, the 
development of sensitive, accurate, and practical diagnostic 
methods is a highly tractable problem, given an appropriate 
level of investment and interest. The development of highly 
sensitive and speciﬁc diagnostic ﬁeld and laboratory tools 
to determine active infection is a crucial requirement for 
moving the entire ﬁeld forward in the research, clinical, and 
public health arenas.
doi:10.1371/journal.pmed.0040332.g002
Figure 2. Interior of House Showing the Type of Wall Construction 
Often Found in Households in Many Endemic Areas
Cracks in walls are commonly found, inhabited by insects, as evidenced 
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Although vector management has been the foundation of 
the overall strategy for prevention of T. cruzi infection, this 
area is also ripe for improvements. Despite the long-held 
promises of vector suppression through residual spraying 
with pyrethroid insecticides, current procedures often fail 
to eliminate triatomine bugs, especially in semiarid rural 
areas and in peridomestic habitats [37]. The lack of simple, 
sensitive tools for early detection of low-density populations 
of triatomine bugs that reappear after insecticide spraying 
undermines the effectiveness of control and elimination 
programs. Traditional high-risk settings require integrated 
control programs that are tailored to local environmental 
and sociocultural characteristics and employ a long-term 
perspective. The bust-and-boom cycles of the recent past, 
largely dependent on available funding, demonstrate that 
the effectiveness of Chagas disease vector control as currently 
practiced is limited. 
On the other hand, progress in related research can help 
counter these shortcomings in vector control strategies. Our 
understanding of the eco-epidemiology of infection has 
signiﬁcantly improved in recent years, especially with the 
application of geospatial analytical tools. These advances 
have allowed the development of infection and disease 
transmission models [38] as well as the more targeted 
planning of prevention and control strategies coupled with 
continued surveillance (e.g., identiﬁcation of so-called 
transmission “hotspots” or loci of bug re-infestation) [39]. 
Several tools to prevent infection and to control (peri-)
domestic bug populations have been evaluated, including 
insecticide-treated bed-nets [40] and dog collars [41], and 
optimum insecticide doses in peridomestic habitats. These 
tools have been shown to effectively reduce the contact 
of humans or reservoir dogs with the triatomine vector of 
T. cruzi. Bed-nets and collars would become particularly 
attractive options if they were used in an integrated approach 
aimed at controlling other vector-borne diseases such as 
malaria and leishmaniasis, respectively. The key issue is 
whether or not these new tools can be applied successfully at 
geographic scales ranging from individual villages to entire 
regions where current methods are not sufﬁcient for the 
desired objective (control versus elimination).
Glimmer of Hope
The problems of Chagas disease are many, but they are 
not insurmountable. There are numerous partial solutions 
already at hand that, if used in a coordinated manner, 
and with consideration of the unique characteristics of 
endemic areas (e.g., rural underdevelopment, poverty, lack 
of adequate housing, and increasingly decentralized health 
services), could have a signiﬁcant impact. The entities that 
will fund and coordinate such an integrated effort remain 
to be identiﬁed, but clearly the involvement of the public 
sector is essential. Better diagnostics, drugs, and improved 
approaches to vector control programs will require more 
and better research, sharper focus, and greater rigor on the 
part of the research community. In addition,  contributions 
from governments, the private sector, and nongovernmental 
organizations will be needed to establish the infrastructure 
for testing drugs and control methods as well as the platforms 
to develop and implement effective and affordable diagnostic 
tests. Fortunately, the research community has provided the 
majority of potential drug, vaccine, and diagnostic candidates 
doi:10.1371/journal.pmed.0040332.g003
Figure 3. Cineventriculogram of a 49-Year-Old Male with Chagas Heart Disease
The picture shows the apical aneurysm (sacular) with normal coronary arteries.PLoS Medicine  |  www.plosmedicine.org 1856 December 2007  |  Volume 4  |  Issue 12  |  e332
and, via the sequencing of the T. cruzi genome and proteomes 
[42,43], has presented multiple leads for drug targets and 
diagnostic/vaccine candidates. However, neither for-proﬁt 
nor nonproﬁt companies have taken on the challenges 
of developing these leads further. Effective scientiﬁc, 
philanthropic, and political leadership and forward-thinking 
coordination of a community effort in this realm, at both 
local and regional levels, is badly needed if we want to make 
signiﬁcant inroads into this devastating disease. Ultimately, 
the success of such efforts will be heavily dependent on the 
long-term stability and prospects for economical, societal, and 
political development in the Americas.  
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